Navigation Links
Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
Date:9/18/2007

ly conducting a Phase 1 trial in Canada with a second p38 kinase inhibitor resulting from the collaborative research program.

Under the terms of the companies' ongoing collaboration, Pharmacopeia will receive milestone payments for the p38 compounds in the program to the extent the program progresses through clinical development, and royalty payments for any product from the program that reaches the marketplace. Bristol-Myers Squibb is solely responsible for further development and commercialization of the therapeutic candidate.

ABOUT PHARMACOPEIA

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) for hypertension and diabetic kidney disease for which a Phase 2 clinical trial is underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia's collaborative efforts have resulted in a portfolio that includes two partnered programs that have advanced into Phase 2 clinical trials targeting chronic obstructive pulmonary disease (COPD) and psoriasis and two partnered programs in Phase 1 clinical trials targeting oncology and inflammatory disease. Four additional partnered compounds are in preclinical development. Pharmacopeia's current strategic alliances are with Cephalon, GlaxoSmithKline, Organon and Wyeth.

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based u
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... NORTHVALE, N.J. , Sept. 29, 2014 /PRNewswire/ ... announced that it has entered into an affiliation ... based in Cambridge, Massachusetts ... recently appointed member of ADMT,s Advisory Board. ... foreign medical technology companies with specialized services and ...
(Date:9/29/2014)... 29, 2014  Diplomat, the nation,s largest independent ... has been named chief information officer. As CIO, ... information technology department while being responsible for strategic ... external partnerships. Prior to joining Diplomat, ... the development of technology architectures and organizational solutions, ...
(Date:9/29/2014)... 29, 2014 Novogen Ltd. (ASX: NRT, NASDAQ: ... , conducted an interview with ABC TV that was broadcast ... bulletin and on the following day on Weekend Breakfast. The ... Trilexium, into the clinic in Australia ... multiforme. The interview provides certain new information ...
Breaking Medicine Technology:ADM Tronics Joins Triotech Ventures Technology Consortium 2ADM Tronics Joins Triotech Ventures Technology Consortium 3Diplomat names Stephen S. Brown chief information officer 2ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain Cancer 2ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain Cancer 3
... , CHICAGO, Aug. 25 Yesterday,s trends ... to the coolest new movie, youngsters are looking for the ... of products to incorporate the innovative play contemporary kids ask ... an award winning high-tech reading system to a cool new ...
... , PHILADELPHIA, Aug. 24 ... finds that while fatal cervical spine injuries to children in ... girls, in children who were restrained in passenger restraints, and in ... , , Researchers from The Children,s Hospital ...
Cached Medicine Technology:Vtech(R) Delivers Today's Hottest Trends to Tech-Savvy Kids 2Vtech(R) Delivers Today's Hottest Trends to Tech-Savvy Kids 3Vtech(R) Delivers Today's Hottest Trends to Tech-Savvy Kids 4Research Consortium Advances Understanding of Cervical Spine Injuries in Children Involved in Motor Vehicle Crashes 2Research Consortium Advances Understanding of Cervical Spine Injuries in Children Involved in Motor Vehicle Crashes 3
(Date:9/29/2014)... NAPW honors Carmel ... Heaven Sent Consultation , as a 2014 Professional Woman ... prestigious distinction for leadership in marriage and family counseling. ... in the country, spanning virtually every industry and profession, ... vibrant networking community with over 600,000 members and nearly ...
(Date:9/29/2014)... Top10BestSEOHosting.com is a website dedicated ... products. It is headed by a team of ... offers research-based information and factual studies about the ... current market. , Top10BestSEOHosting.com has recently compared ... ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ) and Bluehost are the most ...
(Date:9/29/2014)... According to the senior spokesman for Fecbek, the ... and was worn by a man, Ötzi the Iceman. ... the direction of using small ornamental purses—which evolved into ... a leading online supplier of fashion accessories, has released ... are fashionable. , For most men, they do ...
(Date:9/29/2014)... New York, NY (PRWEB) September 29, 2014 ... parenthood. Some parents get lucky when there little one can ... peep and takes consistent naps each day. For many parents, ... to perform if you're exhausted and consumed with stress. ... just assumed that like other babies she would fall ...
(Date:9/29/2014)... September 29, 2014 Dr. Robert Levinthal, ... 25 years in his hometown, returns to Houston Neuro ... and Spine Center. , Over the last nine years, ... Hospital at Fort Hood and Lubbock. He will utilize ... Excellence devoted to the goal of excellence in neurosurgical ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Carmel T. Ross, Marriage and Family Therapist at Heaven Sent Consultation, a 2014 Professional Woman of the Year 2Health News:Top10BestSEOHosting.com: New Reviews for Linux Web Hosting Suppliers Available Online 2Health News:Mommy Blogger Offers Advice on Getting Your Baby to Sleep 2Health News:Mommy Blogger Offers Advice on Getting Your Baby to Sleep 3Health News:Houston Neuro & Spine Surgery Plans to Develop Center of Neurosurgical Excellence 2
... wide today as it was in the early ,90s, study ... with lung cancer are less likely than white patients to ... Disparities in lung cancer treatments were as large in 2002 ... there have been efforts to decrease those inequalities in treatment, ...
... it is adopting the Nurse-Family Partnership(C) program. Scottish Health ... visit to an established project in Harlem, New York, ... clients and the program,s founder, Dr. David Olds.Nurse-Family Partnership ... visitation services to low income, first-time mothers in 28 ...
... in Market Share Expected for Western Drug Companies, According ... 13 Decision Resources, one of the world,s leading ... issues, finds that the colorectal cancer drug market in ... from $118 million in 2007 to $290 million in ...
... Loma Linda University research just published in the ... effects of walnuts and fatty fish in the fight ... lower cholesterol more than fish, while fatty fish lower ... heart disease."The practical significance of the study is that ...
... On April 7, 2009, the Boston District ... CoolTouch Inc. after CoolTouch signed a settlement agreement with Dr. ... in 2004 and relates to the use of lasers for ... and pay royalties on CTEV laser sales and accessories that ...
... ability to scan, store and retrieve archived files without making extensive ... ... (PRWEB) April 13, 2009 -- Olympic Physical Therapy and ... provides quality rehabilitation and prevention services at four locations throughout Rhode ...
Cached Medicine News:Health News:Blacks Less Likely to Get Optimal Lung Cancer Treatment 2Health News:Scotland Announces Establishment of Nurse-Family Partnership Program 2Health News:Chinese Colorectal Cancer Drug Market Will More Than Double by 2012 2Health News:Walnuts and Fish Protect Against Heart Disease in Different Ways, According to Newly Published Loma Linda University Research 2Health News:CoolTouch Inc. Settles Diomed Lawsuit, Files Re-examination Request for Cynosure '873 Patent 2Health News:Olympic Physical Therapy Clears Space and Reduces Clutter with Hosted Document Management Solution from DocuSyst 2Health News:Olympic Physical Therapy Clears Space and Reduces Clutter with Hosted Document Management Solution from DocuSyst 3
... 5500s electronic architecture incorporates advanced circuit designs ... it HI VUE an engineering philosophy ... to individual specifications while, at the same ... system. The end result is extraordinary performance ...
... The EG-3630UR is a radial-type endoscope ... new technology gives a flicker-free, high-resolution image ... an optical system for direct visual observation. ... of performance as an endoscope as well ...
... an affordable solution for low volume workloads, ... menu includes a variety of clotting assays, ... ACL 1000 also offers bar code capability ... Plus, it's backed by superior technology that ...
... The SYNCHRON CX4-S system consolidates ... tests in one workstation, targeted ... processes 50-200 samples per day. ... systems, the CX4-S is easy ...
Medicine Products: